What The Delay Of A Promising Muscular Dystrophy Drug Means For Patients, Investors And All Of Biotech
Published: Nov 13, 2013
In the late 1990s Regeneron, the biotechnology company based in Tarrytown, NY, was developing a treatment for amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease, which cause paralysis and then death. The company had synthesized a protein missing in people with the disease, and patients reported amazing improvements in symptoms.
Help employers find you! Check out all the jobs and post your resume.